Hepatitis C Virus-Related One-Year Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial
ConclusionDirect-acting antiviral usage after complete hepatocellular carcinoma ablation significantly decreases the 1-year HCC recurrence rates, but the risk of recurrence is still not eliminated. The study registration number onclinicaltrials.gov: NCT04653818 (initial release on 28/11/2020).
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Gastroenterology | Hepatitis | Hepatitis C | Hepatocellular Carcinoma | Liver Cancer | Statistics | Study